Affordable Access

deepdyve-link
Publisher Website

Improved Executive Function in Adults Diagnosed With Attention-Deficit/ Hyperactivity Disorder as Measured by the Brown Attention-Deficit Disorder Scale Following Treatment With SHP465 Mixed Amphetamine Salts Extended-Release: Post Hoc Analyses From 2 Randomized, Placebo-Controlled Studies.

Authors
  • Brown, Thomas E1
  • Chen, Jie2
  • Robertson, Brigitte3
  • 1 Keck School of Medicine of the University of Southern California, Los Angeles, and Brown Clinic for Attention & Related Disorders, Manhattan Beach, CA, USA.
  • 2 Takeda Pharmaceuticals, Lexington, MA, USA.
  • 3 Shire, a member of the Takeda group of companies, Lexington, MA, USA.
Type
Published Article
Journal
Journal of Attention Disorders
Publisher
SAGE Publications
Publication Date
Jan 01, 2022
Volume
26
Issue
2
Pages
256–266
Identifiers
DOI: 10.1177/1087054720961819
PMID: 33150816
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Assess executive function (EF) improvement with SHP465 mixed amphetamine salts (MAS) extended-release in adults with attention-deficit/hyperactivity disorder (ADHD) using responder analyses of the Brown Attention-Deficit Disorder Scale (BADDS). Post hoc analyses examined data from placebo-controlled SHP465 MAS dose-optimization (12.5-75 mg) and fixed-dose (25-75 mg) studies. Treatment response was assessed using two definitions (BADDS total score at endpoint <50 [no EF impairment] vs. ≥50 [impaired]; BADDS total score at endpoint relative to the in-treatment 90% CI range for baseline total score [below the range = improved]). Response rates (SHP465 MAS vs. placebo) favored SHP465 MAS (all nominal p < .0001) in the dose-optimization (BADDS <50: 41.9% vs. 19.2%; below 90% CI range: 57.4% vs. 29.6%) and fixed-dose (BADDS <50: 51.9% vs. 16.7%; below 90% CI range: 70.6% vs. 32.3%) studies. Improvement in EF measured by BADDS response rates was approximately 2-fold greater with SHP465 MAS than placebo.

Report this publication

Statistics

Seen <100 times